PNEUMOCOCCAL DISEASE

This study tests a new pneumococcal vaccine (PG4) in healthy children aged 15 months to 18 years. About 1,200 participants will receive either the new vaccine or the current Prevnar 20. Researchers will compare safety and immune response over 6 months. The goal is to see if the n…

This study tests a new pneumococcal vaccine in healthy infants to see if it is safe and works better than the current vaccine. About 3,230 babies will receive either the new vaccine or the existing one at routine checkups. Researchers will compare side effects and immune response…

This study tests a new pneumococcal vaccine in about 2400 healthy infants starting at 2 months old. The goal is to see if the new vaccine is as safe as the current vaccine, Prevnar 20, and if it can protect against more types of bacteria that cause pneumonia, meningitis, and ear …

This study tests whether two different pneumococcal vaccines can create antibodies that kill newly discovered types of pneumonia bacteria. Researchers will give healthy adults one of the vaccines and measure how well their immune system fights these bacteria. The goal is to see i…

This early-stage study will give 12 healthy adults a killed whole-cell pneumococcal vaccine called Gamma-PN. The main goal is to collect blood samples to help develop and validate lab tests that measure immune responses. The study does not aim to prove the vaccine works in people…